Hepatocellular Carcinoma
Conditions
Interventions
Trial Group: Postoperative antiviral drug was converted from ETV to TDF
Control Group:Postoperative antiviral drug continued to use ETV
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18-70 years; 2. Primary hepatocellular carcinoma was diagnosed for the first time, and the pathological result was hepatocellular carcinoma; 3. Radical operation (hepatectomy) for liver cancer; 4. BCLC is staged as 0 or A; 5. Preoperative antiviral therapy only received ETV; 6. Liver function Child Pugh score A; 7. ECOG score 0; 8. Understand and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with recurrent hepatocellular carcinoma; 2. Complicated with large vessel invasion; 3. Complicated with HCV, HIV infection or other serious infections; 4. Patients with other malignant tumors; 5. Patients with mental illness; 6. Patients who have participated in other clinical trials in recent three months; 7. Serious diseases with non malignant tumors will affect the patient's compliance or put the patient at risk; 8. Have received anti-tumor treatment before operation; 9. He has received other antiviral treatment except ETV in the past.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| recurrence-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival; | — |
Countries
China
Contacts
Public ContactWei Peng
West China Hospital of Sichuan University
Outcome results
None listed